

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicant** 

: Clarence N. Ahlem, et al.

Application No.

: 10/607,035

Filed

: June 25, 2003

Title

: Pharmaceutical Compositions and Treatment Methods - 4

10 Examiner : Barbara P. Badio

Art Unit

: 1616

Customer No.

: 26551 Confirmation No.: 6394

15

## AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

20 Mail Stop Amendment **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

25

30

Dear Sir:

Applicants submit this paper in response to the restriction requirement the Office mailed on September 9, 2004. Applicants respectfully request the Examiner to enter the following amendments before examination on the merits. The amendments introduce no new matter. Provision for extension of time accompanies this paper.

Amendments to the claims begin on page 2 of this paper.

Remarks begin on page 8 of this paper.

35

02/08/2005 NVILLARI 00000004 501536

10607035

01 FC:2202

75.00 DA

	Claim	Support
5	66, 67 73	named trisubstituted compounds: $3\beta$ , $16\alpha$ , $17\beta$ -trihydroxy- $5\alpha$ -androstane is compound 1.1.6.2 in group 1 at paragraphs 156 and 157; $3\alpha$ , $16\beta$ , $17\beta$ -trihydroxy- $5\alpha$ -androstane is compound 1.1.6.2 in group 37 at paragraph 202, etc.
	57, 61	support for atopic asthma and other listed inflammation conditions is at paragraphs 319, 526, etc.
10	68	support for formulations comprising one or more excipients is at paragraph 271, etc.
	74, 75 76	support for parenteral, oral, buccal, sublingual, aerosol formulations is at paragraphs 271-273, etc.
15	75	support for non-aqueous formulations containing less than 0.3% v/v water is at paragraph 366, etc.; support for suspension in an aqueous liquid formulation is at paragraph 273, etc.

Please charge any additional fees, incuding any fees for additional extension of time, or credit overpayment to Deposit Account No. 501536.

Respectfully submitted,

Hollis-Eden Pharmaceuticals, Inc.

25

20

Date: <u>Dec 21, 2004</u> By: <u>Davy</u>

Daryl D. Muenchau, Reg. No. 36,616 Hollis-Eden Pharmaceuticals, Inc.

4435 Eastgate Mall, Suite 400 San Diego, CA 92121

P: 858-320-2569 F: 858-558-6470

30